The national contract covers FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne RNA, and FoundationOne Heme.

Accurate detection of EBV in tumors is essential for refining diagnosis and guiding management of EBV-associated cancers. This validation study evaluated the performance of the FoundationOne CDx (F1CDx) and FoundationOne Heme (F1H) next-generation sequencing (NGS) assays for detecting EBV compared to the reference standard EBV-encoded RNA (EBER) in situ hybridization (ISH). A total of 413 samples of gastric carcinoma, squamous cell carcinoma (predominantly nasopharyngeal carcinoma), and diffu...

中外製薬は、FoundationOne CDx がんゲノムプロファイルについて、BRAF V600変異及びBRAF融合遺伝子陽性の神経膠腫に対するトボラフェニブのコンパニオン診断として2026年6月17日に厚生労働省の承認を取得したと発表した。対応するがん種は9種に拡大した。

With these approvals, Foundation Medicine now has nine companion diagnostic indications for prostate cancer, the most of any company1BOSTON – June 1, 2026 – Foundation Medicine, Inc., a global, patien...

Fleury (FLRY3) assume a operação dos testes FoundationOne da Roche no Brasil e amplia sua presença em oncologia de precisão e medicina genômica.

The FoundationOne CDx tests are approved for ID of patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer.

Foundation Medicine previously received companion diagnostic approval for its FoundationOne Liquid CDx assay alongside EMD Serono's Tepmetko.

Foundation Medicine previously received companion diagnostic approval for its FoundationOne Liquid CDx assay alongside EMD Serono's Tepmetko.

The initiative now includes Foundation Medicine's FoundationOne Liquid CDx assay to test new therapy combinations in select groups of adults and children with cancer.

The companies will use the FoundationOne Heme platform to identify patients with acute leukemia who have a KMT2A rearrangement or NPM1 mutations.

The FoundationOne test can be used to identify patients with relapsed or refractory BRAF-altered pediatric low-grade glioma who may be eligible for therapeutic options.

This study evaluated an ultraviolet (UV) mutational signature classifier applied to circulating tumor DNA (ctDNA) in cell-free DNA (cfDNA) liquid biopsies, using the FoundationOne Liquid CDx (F1LCDx) platform. Among 73,790 samples, 12.9% (9,527) met the variant threshold for signature analysis, with UV signatures detected in 3.8% (365) of cases. Of these, 51.5% (188) were initially submitted as cutaneous, 8.5% (31) as unspecified primary, and 40.0% (146) as extra-cutaneous tumors. The UV clas...

This study evaluated an ultraviolet (UV) mutational signature classifier applied to circulating tumor DNA (ctDNA) in cell-free DNA (cfDNA) liquid biopsies, using the FoundationOne Liquid CDx (F1LCDx) platform. Among 73,790 samples, 12.9% (9,527) met the variant threshold for signature analysis, with UV signatures detected in 3.8% (365) of cases. Of these, 51.5% (188) were initially submitted as cutaneous, 8.5% (31) as unspecified primary, and 40.0% (146) as extra-cutaneous tumors. The UV clas...

Accurate detection of EBV in tumors is essential for refining diagnosis and guiding management of EBV-associated cancers. This validation study evaluated the performance of the FoundationOne CDx (F1CD...

Abstract. BACKGROUND: The BRAF inhibitor encorafenib plus the anti-EGFR antibody cetuximab improved overall survival, objective response rate, and progression-free survival in previously treated BRAF ...